Fig. 2
From: Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Enhanced antigrowth activity of vorinostat combined with cisplatin in SCLC cells. a H209 and b H146 cells were treated with various concentrations of vorinostat (0.1 and 0.5 μM and 0.1 and 0.2 μM, respectively), cisplatin alone (5 μM), and combinations of the 2 drugs for 24 h. Cell viability was assessed using the MTS assay, and data were represented as mean ± SD in triplicate. A significant reduction in cell viability was documented (*, P < 0.05; ***, P < 0.001) compared with that in vorinostat or cisplatin alone